__NUXT_JSONP__("/drugs/Anti-HER2PBD-MA_Antibody-drug_Conjugate_DHES0815A", (function(a,b,c,d){return {data:[{drug:{slug:b,emaEpar:[],fdaDrugLabel:[],id:b,nciThesaurus:{casRegistry:a,chebiId:a,chemicalFormula:a,definition:"An antibody-drug conjugate (ADC) consisting of a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) linked to a DNA minor groove crosslinking agent pyrrolo[2,1- c][1,4]benzodiazepine monoamide (PBD-MA), with potential antineoplastic activity. Upon intravenous administration of ADC DHES0815A, the monoclonal antibody moiety targets and binds to HER2 expressed on tumor cells. Following receptor internalization and lysosome-mediated cleavage, the cytotoxic PBD-MA moiety is released. In turn, the imine groups of the PBD-MA moiety bind to and crosslink specific sites of DNA, resulting in DNA strand breaks, cell cycle arrest, and cell death in HER2 expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.",fdaUniiCode:"1E55T9OY5I",identifier:"C155940",preferredName:c,semanticType:"Pharmacologic Substance",subclassOf:["C155712"],synonyms:["ADC DHES0815A","Anti-HER2\u002FPBD-MA ADC DHES0815A",c,"Anti-HER2\u002FPBD-Monoamide ADC DHES0815A","DHES-0815A","DHES0815A"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FAnti-HER2PBD-MA_Antibody-drug_Conjugate_DHES0815A",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("","Anti-HER2PBD-MA_Antibody-drug_Conjugate_DHES0815A","Anti-HER2\u002FPBD-MA Antibody-drug Conjugate DHES0815A","2021-10-30T13:34:15.583Z")));